BaseLaunch

What BaseLaunch does

BaseLaunch is a biotech venture incubator and funding program founded in 2018 and based in Allschwil, Switzerland, operated as an initiative of Basel Area Business & Innovation (a Swiss association under Art. 60 et seq. of the Swiss Civil Code). It partners with scientists, entrepreneurs, and academic spin-offs to launch and grow early-stage biotech companies developing cutting-edge therapeutics, with a particular focus on pre-seed to seed-stage ventures — including those where only a Post Doc or Professor founder is involved. Its core offering combines convertible loan financing of up to CHF 500,000 per venture with access to a global pharma partner network (Roche, Novo Nordisk, AbbVie, CSL, Johnson & Johnson, Takeda, and Pfizer), introductions to venture investors such as Pureos Bioventures, company and team-building support, and access to laboratory and related infrastructure through domain partners including Lonza, Wuxi AppTec, Wuxi Biologics, Catalent, and BioDuro.

The program operates through structured application cycles with defined deadlines (the next being September 4, 2026) and is supplemented by pharma partner referrals. Its commercial model is not fee-based in a conventional SaaS sense; instead, BaseLaunch derives value from equity and convertible note exposure in portfolio companies, with strategic investments from pharma partners and co-financing from regional government partners (Canton Basel-Stadt, Canton Basel-Landschaft, and Switzerland Innovation Park Basel Area) supporting operations. Since 2018 it has supported 27 portfolio companies that have collectively raised over US$1 billion in follow-on financing, with six entering clinical development and one acquired for US$500 million. Recent additions include Umlaut.bio (EUR 3 million pre-seed extended via BaseLaunch), Cancentus (up to CHF 500,000 convertible loan), and Aukera Therapeutics (portfolio addition December 2025), alongside ongoing pharma partner expansion through AbbVie (May 2024), Takeda (December 2025), and Pfizer (February 2026).

Name

BaseLaunch

Legal name

Basel Area Business & Innovation

Website

https://www.baselaunch.ch/

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Biotech Venture Incubation

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Accelerators & Incubators (Investor-Operated) (FSANAAAM)

akta.pro secondary industries

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD), Corporate Accelerators & Startup Programs (FSANAHAD)

Keywords

• Biotech venture incubation
• Therapeutics accelerator program
• Convertible loan financing
• Pharma partnership deals
• Biotech startup funding

Headquarters

HQ city

Allschwil

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Incubator Program Services: BaseLaunch provides funding of up to CHF 500,000 in convertible loan financing to early-stage biotech ventures in exchange for equity or convertible notes. The program generates value through portfolio company success and provides access to pharma partners seeking deal flow and innovation pipelines.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

BaseLaunch is a biotech venture incubator and funding program that partners with scientists and entrepreneurs to launch and grow early-stage companies developing cutting-edge therapeutics. Selected ventures receive up to CHF 500,000 in convertible loan financing, hands-on company and team-building support, introductions to seven global pharma partners and venture capital investors, IP and legal advisory services, and access to laboratory space and related infrastructure. The program targets pre-seed to seed-stage biotechs, including academic spin-offs and projects with only a Post Doc or Professor founder.

Product overview

BaseLaunch operates as a single unified biotech venture incubator program — not a modular software platform — that provides end-to-end support for early-stage therapeutics companies. Its core offering combines convertible loan financing of up to CHF 500,000, direct introductions to a network of global pharmaceutical partners (including Roche, Novo Nordisk, AbbVie, CSL, Johnson & Johnson, Takeda, and Pfizer) and venture capital investors, hands-on company and team-building assistance, and access to laboratory space and related infrastructure. The program is designed to take biotech ventures from pre-seed through to Series A readiness.

Differentiator

Problem solved

Functional benefit

Products and services

• BaseLaunch Venture Incubator Program A biotech venture incubator program that partners with scientists and entrepreneurs to launch, fund, and build early-stage biotech companies developing cutting-edge therapeutics. The program offers convertible loan financing, direct access to seven global pharmaceutical partners and venture capital investors, hands-on company and team-building support, IP and legal advisory services, and access to laboratory infrastructure. It targets pre-seed to seed-stage ventures, including academic spin-offs and projects with only a Post Doc or Professor founder.
• Convertible Loan Financing (up to CHF 500,000) Early-stage financing offered to selected biotech ventures, structured as a convertible loan of up to CHF 500,000, to fund proof-of-concept data generation, team building, and preparation for seed and Series A rounds. The financing is designed to preserve founder ownership while providing the capital needed to reach Series A readiness.

Quantifiable outcome

• Portfolio companies have collectively raised over $1 billion
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

20 partnerships are on record, tiered domain, core and regional.

• LonzadomainTechnology or Integration · 1 March 2026Lonza renewed its partnership as a Domain Partner, providing early-stage ventures with access to world-class expertise in drug development and manufacturing across biologics, cell and gene therapies, and advanced therapeutic platforms.
• VossiusdomainImplementation/ SI/ Consulting Partner · 1 March 2026Vossius renewed its partnership to support early-stage biotechs in protecting and strengthening innovations. The patent law firm offers full-service IP expertise across Europe, US, Japan, Taiwan, and Korea.
• PfizercoreStrategic or Co-development Partner · 1 February 2026Pfizer became the seventh pharma partner. Through this strategic investment, Pfizer gains access to life sciences deal flow in Central Europe and company-building capabilities while providing expertise to startups.
• CatalentdomainTechnology or Integration · 1 January 2026Catalent is a global contract development and manufacturing organization (CDMO) supporting pharmaceutical, biotech and consumer health companies with drug development and manufacturing solutions.
• TakedacoreStrategic or Co-development Partner · 1 December 2025Takeda joined as a pharmaceutical partner through strategic investment. Alison Handley, Head of the Center for External Innovation at Takeda, stated the partnership strengthens connection to European biotech innovation.
• BioDurodomainTechnology or Integration · 1 July 2025BioDuro is a trusted CRDMO (contract research, development and manufacturing organization) with a 29-year track record providing end-to-end services for pharmaceutical and biotech companies.
• AbbViecoreStrategic or Co-development Partner · 1 May 2024AbbVie joined as a partner with strategic investment and active role in investment decisions. Christian Schubert, VP and Head of AbbVie Ventures, noted they aim to leverage AbbVie's expertise in translating innovative science into novel therapeutics.
• RochecoreStrategic or Co-development Partner · 1 January 2018Roche is a founding pharma partner of BaseLaunch. James Sabry, Global Head of Roche Pharma Partnering, has stated continued commitment to BaseLaunch, noting Basel's significance as a leading life sciences hub.
• Novo NordiskcoreStrategic or Co-development PartnerNovo Nordisk is a pharma partner providing access to deal flow and biotech innovation expertise.
• CSLcoreStrategic or Co-development PartnerCSL (specifically CSL Behring) is a pharma partner. Dr. Adrian Zuercher, VP Research Europe and Head of Plasma Protein Research, stated the partnership helps identify potential external collaborators from throughout Europe.
• Johnson & JohnsoncoreStrategic or Co-development PartnerJohnson & Johnson Innovation is a pharma partner. Nerida Scott, Head of J&J Innovation, noted they have been collaborating since BaseLaunch launch in supporting early-stage biotech ventures.
• Wuxi AppTecdomainTechnology or IntegrationWuxi AppTec is a domain partner providing access to integrated services for biopharmaceutical companies.
• Wuxi BiologicsdomainTechnology or IntegrationWuxi Biologics is a domain partner supporting early-stage ventures with biologics development services.
• Walder WyssdomainImplementation/ SI/ Consulting PartnerWalder Wyss is a leading Swiss law firm domain partner providing legal counsel to portfolio companies during financing rounds.
• VISCHERdomainImplementation/ SI/ Consulting PartnerVISCHER is a law firm domain partner offering expertise in IP protection, licensing, and industry collaboration agreements for biotech startups.
• Hoffmann & PartnerdomainImplementation/ SI/ Consulting PartnerHoffmann & Partner is an independent financial advisory firm domain partner specializing in M&A and CFO services for Swiss and international companies, offering part-time and interim CFO services to biotech startups.
• KPMGdomainImplementation/ SI/ Consulting PartnerKPMG is a global professional services firm and domain partner providing financial advisory and consulting services.
• Basel LandschaftregionalOthersCanton of Basel-Landschaft is a regional partner supporting the Basel Area innovation ecosystem.
• Canton Basel StadtregionalOthersCanton of Basel-Stadt is a regional partner and home to the Basel Area innovation hub.
• Switzerland Innovation ParkregionalOthersSwitzerland Innovation Park Basel Area is a regional partner hosting the innovation ecosystem.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Petri: Biotech accelerator focused on early-stage therapeutics companies, providing seed funding and resources to academic spinouts — comparable emerging player in biotech venture creation.

Direct peers

• LabCentral: Cambridge, MA biotech incubator offering lab space and operational support to early-stage therapeutic ventures — directly comparable as a physical incubator with pharma sponsor relationships.
• BioGenerator: St. Louis-based biotech venture studio/accelerator that funds and builds early-stage therapeutics companies, analogous to BaseLaunch's pre-seed/seed model with deep regional pharma and academic ties.
• MBC BioLabs: Bay Area biotech incubator offering lab infrastructure, community, and partner access to early-stage therapeutic ventures — closely comparable to BaseLaunch's lab + pharma-network offering.
• Apollo Therapeutics: UK-based therapeutics venture builder funded by major pharma (AstraZeneca, GSK, J&J) that translates academic science into biotech startups — analogous pharma-funded company-creation model.
• IndieBio: Biotech accelerator program providing seed funding, mentorship, and lab access to early-stage biology startups, with a comparable venture-creation thesis to BaseLaunch.
• Pureos Bioventures: Swiss-based early-stage biotech VC and BaseLaunch financial partner, investing in pre-seed through Series A therapeutics — directly comparable investment mandate and overlapping portfolio.

Broad incumbents

• JLABS (Johnson & Johnson Innovation): Global pharma-incubator network providing lab space, mentorship, and capital to early-stage biotech ventures. BaseLaunch's pharma-partner model echoes JLABS but is regional and multi-sponsor.
• EIT Health: European health innovation network supporting early-stage healthcare startups with accelerator programs, funding, and ecosystem access — broader geographic version of BaseLaunch's mandate.
• Y Combinator: Premier technology accelerator with a growing biotech/healthcare vertical — relevant as a global benchmark for accelerator-stage investing and convertible note mechanics BaseLaunch also uses.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/baselaunch
• LinkedInlinkedin.com/company/baselaunch

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments13 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BaseLaunch